Baird raised the firm’s price target on Crinetics to $52 from $45 and keeps an Outperform rating on the shares. The firm said they expect positive results from the PATHFNDR-2 Phase 3 study next month, the initiation of Phase 3 program in carcinoid syndrome later this year and initial CAH data next quarter.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRNX:
- Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
- Is CRNX a Buy, Before Earnings?
- Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)